Europe Allows Derogation of Atypical Actives from ICH Q7
This article was originally published in The Gold Sheet
The European Medicines Agency tackled the issue of atypical actives in 2008, David Cockburn, head of manufacturing quality compliance at EMA, told a recent PDA workshop in Bethesda, Md.
You may also be interested in...
As the pharmaceutical supply chain comes under increased regulatory scrutiny, FDA inspectors are finding manufacturers using excipients as active ingredients, even though they don’t meet active ingredient standards, and the industry is talking about establishing a new set of standards for these so-called atypical actives, and perhaps coaxing FDA into ratifying them via guidance.
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.